Accurate accounting of caplacizumab cost effectiveness – Authors' reply. Issue 5 (May 2021)

Record Type:: Journal Article
Title:: Accurate accounting of caplacizumab cost effectiveness – Authors' reply. Issue 5 (May 2021)
Main Title:: Accurate accounting of caplacizumab cost effectiveness – Authors' reply
Authors:: Hughes, Mary
Elliot, Nicole
Adler, Amanda I
Abstract:
Is Part Of:: Lancet. Volume 8:Issue 5(2021)
Journal:: Lancet
Issue:: Volume 8:Issue 5(2021)
Issue Display:: Volume 8, Issue 5 (2021)
Year:: 2021
Volume:: 8
Issue:: 5
Issue Sort Value:: 2021-0008-0005-0000
Page Start:: e316
Page End:
Publication Date:: 2021-05
Subjects:: Hematology -- Periodicals
Blood -- Diseases -- Periodicals
616.15005
Journal URLs:: http://www.sciencedirect.com/science/journal/23523026 ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/S2352-3026(21)00074-0 ↗
Languages:: English
ISSNs:: 2352-3026
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5146.081555
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 16728.xml